PDPS
LIVE

Serial Number

97933969

Owner

PeptiDream Inc.

Attorney

Harris A. Wolin

Filing Date

May 12, 2023

Add to watchlist:

No watchlists yet
View on USPTO

PDPS Trademark

Serial Number: 97933969 • Registration: 7709587

PDPS is a trademark filed by PeptiDream Inc. on May 12, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

PeptiDream Inc. (3 trademarks)

3-25-23 Tonomachi, Kawasaki-Ku
Kawasaki-Shi, Kanagawa 210-0821 , JP

Entity Type: 03

Trademark Details

Filing Date

May 12, 2023

Registration Date

March 4, 2025

Published for Opposition

January 14, 2025

Goods & Services

Manufacture of synthetic peptides to the order and specification of others; Peptide synthesis for others, namely, manufacture of synthetic peptides to the order and specification of others; Manufacture of pharmaceuticals and chemicals to the order and specification of others; Manufacture of synthetic proteins to the order and specification of others; Amino acid synthesis for others, namely, manufacture of amino acids to the order and specification of others

Synthesized peptides used in drug discovery of various pharmaceuticals for the treatment of various to different diseases and medical conditions; Chemical preparations used in drug discovery for the treatment of various diseases and medical conditions and for pharmaceutical purposes; Central nervous system drugs, namely, pharmaceutical preparations for the treatment of various diseases and medical conditions affecting the central nervous system; Peripheral nerve drugs, namely, pharmaceutical agents for the treatment of various diseases and medical conditions affecting the peripheral nervous system; Drugs affecting sensory organs, namely, pharmaceutical agents for the treatment of various diseases and medical conditions affecting sensory organs; Antiallergic drugs, namely, pharmaceutical antiallergic preparations and substances; Cardiovascular drugs, namely, cardiovascular pharmaceutical preparations; Drugs affecting respiratory organs, namely, pharmaceutical preparations for treating respiratory diseases; Drugs affecting digestive organs, namely, pharmaceutical preparations for the treatment of various diseases and medical conditions affecting digestive organs; Drugs for outer skin, namely, pharmaceutical preparations for the treatment of various diseases and medical conditions for skin care; Pharmaceutical preparations for the treatment of various diseases and medical conditions of Metabolic disorders; Cellular function activating drugs for the treatment of various diseases and medical conditions for medical purposes; Pharmaceutical preparations for the treatment of various diseases and medical conditions for suppressing tumors; diagnostic preparations for medical purposes; Pharmaceutical preparations using synthesized peptides used in drug discovery and pharmaceuticals for the treatment of various diseases and medical conditions for medical purposes; Synthesized proteins and chemical preparations used in drug discovery and pharmaceuticals for the treatment of various diseases and medical conditions for medical purposes

Chemicals for the manufacture of pharmaceuticals; synthesized peptides for scientific and research use; Reagents for biological and chemical purposes and for research purposes, excluding those for medical or veterinary use; Proteins and synthesized peptides used in the research and the development and manufacture of pharmaceuticals and biologicals; Chemical reagents used for the detection, measurement and identification of genetic materials or compounds, excluding those for medical and veterinary use

Testing, examination, namely, inspection and research services in the field of pharmaceuticals, cosmetics, and foods, and the provision of information or advice thereto; Testing, examination, namely, inspection and research services in the field of medical organisms or bacteria, and the provision of information or advice thereto; Testing, examination, namely, inspection and research services in the field of chemistry, and the provision of information or advice thereto; Testing, examination, namely, inspection and research services in the field of medical care, and the provision of information or advice thereto; Testing, examination, namely, inspection and research services in the field of biotechnology, and the provision of information or advice thereto; Testing, examination, namely, inspection and research services in the field of the identification of hit lead peptides, and the provision of information or advice thereto; Testing, examination, namely, inspection and research services in the field of the identification of hit-lead compounds, and the provision of information or advice thereto; Testing, examination, namely, inspection and research services in the field of the analysis and synthesis of peptides, and the provision of information or advice thereto; Testing, examination, namely, inspection and research services in the field of the analysis and synthesis of proteins, and the provision of information or advice thereto; The generation of a library of peptides and the provision of information or advice thereto; Testing, examination, namely, inspection and research services in the fields of pharmaceuticals, cosmetics, foods, medical organisms or bacteria, chemistry, medical care, biotechnology, identification of hit lead peptides, analysis and synthesis of peptides, using automated screening machines and the provision of information or advice thereto; Scientific research in the nature of conduction of clinical trials for others; Quality control of peptides used in drug development; Advice on quality control of peptides used in drug development

Filing History

REGISTERED-PRINCIPAL REGISTER
Mar 4, 2025 R.PR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Mar 4, 2025 NRCC
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 14, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jan 14, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 8, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 18, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 17, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 17, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 17, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 17, 2024 CNEA
DATA MODIFICATION COMPLETED
Dec 13, 2024 DMCC
ASSIGNED TO LIE
Dec 13, 2024 ALIE
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 10, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 10, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 10, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 24, 2024 GNRN
NON-FINAL ACTION E-MAILED
Sep 24, 2024 GNRT
NON-FINAL ACTION WRITTEN
Sep 24, 2024 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 18, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 18, 2024 CRFA
ASSIGNED TO LIE
Sep 18, 2024 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 7, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 7, 2024 GNRN
NON-FINAL ACTION E-MAILED
Feb 7, 2024 GNRT
NON-FINAL ACTION WRITTEN
Feb 7, 2024 CNRT
ASSIGNED TO EXAMINER
Feb 6, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 12, 2023 NWOS
NEW APPLICATION ENTERED
May 16, 2023 NWAP